Galapagos delivers candidate drug in GSK alliance, receives €6.7 million

08-Mar-2011 - Belgium

Galapagos NV announced that it delivered a fourth candidate drug in its arthritis alliance with GlaxoSmithKline (GSK) in December 2010.  This achievement triggered a €6.7 million milestone payment to Galapagos, which was included in 2010 revenues.

This latest pre-clinical candidate is a small molecule that meets the chemical and biological criteria set by GSK for a potential new medicine.  Galapagos will now start scale-up chemistry and comprehensive safety evaluation, with the aim to initiate Phase I clinical trials in early 2012.

"The arthritis alliance with GSK has been very fruitful in delivering promising candidate drugs," said Onno van de Stolpe, CEO of Galapagos.  "In this alliance, we currently have two clinical trials, with plans to progress this new candidate into the clinic next year."

Other news from the department research and development

Most read news

More news from our other portals